Zealand pauses development of GLP-1/GLP-2 obesity candidatenews2025-11-13T11:50:28+00:00November 13th, 2025|Endpoints News|
Novartis says Phase 3 data prove new antimalarial could address resistancenews2025-11-12T22:00:50+00:00November 12th, 2025|Endpoints News|
FDA announces new regulatory pathway for personalized rare disease therapiesnews2025-11-12T22:00:19+00:00November 12th, 2025|Endpoints News|
Chinese biotechs are shedding their fast-follower reputations as innovation surgesnews2025-11-12T18:18:10+00:00November 12th, 2025|Endpoints News|
Immatics shares early bispecific data as it seeks to make its name beyond cell therapynews2025-11-12T16:42:44+00:00November 12th, 2025|Endpoints News|
Top biopharma execs set to appear at MAHA Summitnews2025-11-11T19:12:13+00:00November 11th, 2025|Endpoints News|
EnGene posts more pivotal data for bladder cancer gene therapy, plans 2026 filingnews2025-11-11T12:30:20+00:00November 11th, 2025|Endpoints News|
Neurocrine reports Phase 2 fail for depression drug it licensed from Takedanews2025-11-11T11:40:18+00:00November 11th, 2025|Endpoints News|
#AHA25: Novo Nordisk posts mixed mid-stage data on ATTR-CM drugnews2025-11-10T20:00:37+00:00November 10th, 2025|Endpoints News|
Cogent soars on back of Phase 3 success in stromal tumorsnews2025-11-10T16:30:46+00:00November 10th, 2025|Endpoints News|
